## Does a Single CRISPR Infusion Keep Cholesterol Low for a Full Year?

One-year follow-up data from the phase 1a trial of CTX310 — a lipid nanoparticle-delivered [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) therapy targeting the ANGPTL3 gene — show that reductions in LDL cholesterol, triglycerides, apolipoprotein B, and non-HDL cholesterol are sustained with no new serious adverse events. The data were presented in a late-breaking science session at the European Society of Cardiology Congress 2026 and simultaneously published as a research letter in the *New England Journal of Medicine*, making this the longest reported follow-up for any gene-editing approach targeting a lipid disorder via ANGPTL3.

The 15-patient, open-label, ascending-dose trial enrolled adults with uncontrolled hypercholesterolemia, moderate to severe hypertriglyceridemia, or mixed dyslipidemia. All received a single infusion of CTX310 at doses ranging from 0.1 to 0.8 mg/kg based on estimated lean body weight. No dose-limiting toxicities related to CTX310 were observed through the full one-year follow-up period. The durability result clears the study for progression to phase 1b testing.

The commercial and clinical implications are significant: if a one-time infusion can permanently suppress atherogenic lipoprotein production, the addressable market for patients who fail or cannot tolerate chronic lipid-lowering therapy is substantial.

---

## How CTX310 Works — and Why Hepatocyte Turnover Was the Key Unknown

CTX310's mechanism is grounded in human genetics. Naturally occurring loss-of-function variants in ANGPTL3 — which encodes angiopoietin-like 3, a hepatically produced inhibitor of lipoprotein lipase and endothelial lipase — are associated with lifelong reductions in LDL cholesterol, triglycerides, and atherosclerotic cardiovascular disease risk, without apparent adverse effects in carriers. CTX310 attempts to recreate this state pharmacologically using in vivo editing.

The formulation consists of a lipid nanoparticle encapsulating two components: an mRNA encoding the Cas9 nuclease and a guide RNA targeting ANGPTL3, delivered systemically to induce a permanent loss-of-function mutation in hepatocytes.

The central scientific question heading into the one-year readout was whether hepatocyte turnover would erode the editing effect over time. Cleveland Clinic's Steven Nissen, MD, Chief Academic Officer of the Heart, Vascular & Thoracic Institute and coinvestigator on the trial, framed it directly: "Hepatocytes have a turnover rate of nearly 20% per year, and the average age of adult liver cells is less than three years regardless of a person's age. So what if some of the cells that were not altered are replicating? Does that mean the effect of the gene editing goes away or is diminished?"

The one-year data answered that concern favorably. According to Nissen: "The levels of ANGPTL3 and lipids remained low and flat through the full year, which suggests we're editing the genes so efficiently that when the hepatocytes replicate, the genetic change we've induced is replicated along with them."

This is not a trivial mechanistic point. It implies that the editing efficiency at the initial dose was high enough that even as unedited hepatocytes divide, the edited population remains dominant — a requirement for any genuinely permanent, one-time treatment model.

---

## What the One-Year Data Actually Show

The source material reports mean percentage changes from baseline to one year for patients receiving the highest dose of CTX310 (0.8 mg/kg) across ANGPTL3 protein levels and atherogenic lipoprotein biomarkers (LDL cholesterol, triglycerides, apolipoprotein B, and non-HDL cholesterol). The source does not provide the specific numerical percentages for those changes, so precise figures are not cited here.

What the data confirm:

- **No dose-limiting toxicities** related to CTX310 through 12 months
- **No new serious adverse events** during extended follow-up beyond the initial 60-day report
- **Sustained suppression** of ANGPTL3 protein levels and all four atherogenic lipid biomarkers at one year
- **Well-tolerated profile** across the full dose range in all 15 patients

The initial 60-day data, published in the *New England Journal of Medicine* (2025;393:2119–2130), showed CTX310 to be well tolerated with no dose-limiting toxicities and substantial reductions in ANGPTL3 and atherogenic lipoproteins at the highest doses through that timepoint.

---

## Phase 1b and the 15-Year FDA Surveillance Requirement

The one-year data package was sufficient to advance the program to phase 1b. Luke Laffin, MD, the study's presenter and co-first author, characterized the phase 1a trial as now complete.

The FDA's posture on long-term monitoring sets a precedent worth flagging for the field. According to the source, the FDA has requested 15 years of follow-up for patients enrolled in this trial — described as an unprecedented duration of required surveillance. Nissen was explicit about the rationale: "We need to ensure there are no downstream safety issues from editing a gene, such as malignancy. This type of very long-term follow-up will have to be done for most of" these programs.

*Analysis:* The 15-year surveillance request is not an indictment of the technology — the FDA has made similar requests for other durable genomic medicines. But it is a structural cost and timeline factor that enterprise buyers and investors evaluating CRISPR therapeutics need to price into their models. Programs that generate clean long-term data will benefit disproportionately from any future expedited review pathways the FDA may create for durable gene therapies.

---

## Implications for the Broader In Vivo Gene Editing Field

The CTX310 data land in a competitive context. Laffin noted that two manuscripts describing PCSK9-targeting gene-editing approaches were published after the initial 60-day CTX310 results — indicating the hepatic gene editing space for lipid disorders is active on multiple fronts simultaneously.

The significance of the one-year durability data extends beyond cardiovascular disease. Laffin made this explicit: "This is encouraging for the entire field of CRISPR, because it suggests that a one-and-done treatment approach really might be possible for many of the gene-editing targets now being looked at."

That thesis — that editing efficiency can be high enough to survive hepatocyte turnover and maintain therapeutic effect without re-dosing — is foundational to the business case for in vivo gene editing across metabolic disease, rare disease, and potentially other chronic conditions where the liver is the target organ.

For companies building LNP-delivered CRISPR platforms for hepatic targets, the CTX310 one-year data provide the first clinical evidence at meaningful follow-up that this durability is achievable in humans, not just in animal models. The field now has a benchmark.

---

## Key Takeaways

- CTX310, a lipid nanoparticle-encapsulated CRISPR-Cas9 therapy targeting ANGPTL3, demonstrated durable suppression of LDL cholesterol, triglycerides, apolipoprotein B, and non-HDL cholesterol through one year in a 15-patient phase 1a trial.
- No dose-limiting toxicities or new serious adverse events were observed through 12 months of follow-up.
- The highest dose studied was 0.8 mg/kg delivered as a single infusion; all patients received one infusion only.
- Hepatocyte turnover — the central mechanistic concern for durability — did not diminish the editing effect, suggesting high in vivo editing efficiency at the 0.8 mg/kg dose.
- The FDA has requested 15 years of post-treatment surveillance for trial participants, setting a precedent for long-term safety monitoring of in vivo gene editors.
- The program advances to phase 1b; the one-year NEJM publication and ESC 2026 presentation provide a clinical benchmark for competing PCSK9 and other hepatic gene editing programs.

---

## Frequently Asked Questions

**What is CTX310 and what disease does it treat?**
CTX310 is a lipid nanoparticle-formulated CRISPR-Cas9 therapy designed to induce a permanent loss-of-function mutation in the ANGPTL3 gene in liver cells. It is being developed for refractory dyslipidemia — patients with uncontrolled high LDL cholesterol, high triglycerides, or mixed lipid disorders who do not adequately respond to existing therapies.

**How long do the effects of CTX310 last?**
Based on the phase 1a trial data presented at ESC 2026 and published in the *New England Journal of Medicine*, reductions in ANGPTL3 protein and atherogenic lipoproteins (LDL cholesterol, triglycerides, apolipoprotein B, non-HDL cholesterol) were sustained through the full one-year follow-up period with no attenuation observed.

**Why does hepatocyte turnover matter for CRISPR liver therapies?**
Hepatocytes turn over at roughly 20% per year, meaning that over time, unedited liver cells could theoretically repopulate and dilute the therapeutic effect. The CTX310 one-year data suggest this is not occurring — edited cells appear to replicate with the genetic modification intact — which is a prerequisite for a genuinely one-time treatment.

**What is the FDA requiring for long-term safety monitoring of CTX310?**
The FDA has requested 15 years of follow-up for patients enrolled in the CTX310 phase 1a trial, primarily to monitor for potential downstream safety signals such as malignancy from the genomic edit. This is described by the investigators as an unprecedented duration of required surveillance.

**How does CTX310 compare to PCSK9-targeting gene editors?**
CTX310 targets ANGPTL3 rather than PCSK9. Both are hepatic gene editing strategies for lipid lowering. According to the study authors, at least two manuscripts describing PCSK9-targeting gene-editing approaches were published after the 60-day CTX310 results appeared in late 2025, indicating active parallel development. The CTX310 one-year data currently represent the longest published clinical follow-up for any hepatic gene-editing approach to lipid disorders.